Group 1 - The company announced the election of Mr. Jia Zhaoqiang as an employee director during the employee representative assembly held on November 11, 2025, with his term lasting until the end of the third board's term [1][3] - The election process complied with relevant laws and regulations, ensuring that the number of employee representatives on the board does not exceed half of the total board members [1][3] Group 2 - The company will hold a performance briefing for the third quarter of 2025 on November 20, 2025, from 15:00 to 16:00 at the Shanghai Stock Exchange Roadshow Center [4][5] - Investors can submit questions for the briefing from November 13 to November 19, 2025, and the company will address common concerns during the session [6][7][8] Group 3 - The second extraordinary general meeting of shareholders was held on November 11, 2025, with all proposed resolutions passing without any being rejected [12][13] - The meeting was conducted in accordance with the Company Law and the company's articles of association, with all board members and supervisors present [13][14]

Core Points - The company announced the convening of a workers' representative meeting on November 11, 2025, to elect Mr. Jia Zhaoqiang as the employee director [2] - Mr. Jia's term will commence from the date of approval at the workers' representative meeting until the end of the third board of directors' term [2]

证券代码：688399 证券简称：硕世生物 公告编号：2025-045 江苏硕世生物科技股份有限公司 关于选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 贾兆强，男，1987 年 8 月生，中国国籍，无党派人士，无境外永久居留权， 硕士研究生学历。2010 年 5 月至 2021 年 10 月，历任江苏硕世生物科技股份有 限公司合成部主管、副经理、经理；2021 年 11 月至今，任上海硕颖生物科技有 限公司副总经理。2024 年 8 月至今，任上海超世生物科技有限公司执行董事、 总经理。2023 年 9 月至 2025 年 11 月，曾任公司职工代表监事。 截至目前，贾兆强先生间接持有公司股份 47,859 股。贾兆强先生与公司控 股股东、实际控制人、其他持股 5%以上股份的股东、其他董事、高级管理人员 均不存在关联关系，不存在被中国证监会确定为市场禁入者且尚在禁入期的情形， 未受过中国证监会及其他有关部门的处罚或证券交易所惩戒和公开谴责的情形， 未涉嫌犯罪被司法机关立案侦查或涉嫌违法违规被中国证监会立案 ...

证券代码：688399 证券简称：硕世生物 公告编号：2025-046 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第 三季度的经营成果及财务指标的具体情况与投资者进行互动交流和 沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 江苏硕世生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 13 日（星期四）至 11 月 19 日（星期三） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 sssw@s-sbio.com 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。 江苏硕世生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 25 日发布公司 2025 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计 划于 2025 年 11 月 20 日（ ...

证券代码：688399 证券简称：硕世生物 公告编号：2025-044 江苏硕世生物科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 11 日 （二） 股东大会召开的地点：江苏省泰州市药城大道 837 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 63 | | --- | --- | | 普通股股东人数 | 63 | | 2、出席会议的股东所持有的表决权数量 | 34,754,254 | | 普通股股东所持有表决权数量 | 34,754,254 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 41.4373 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 41.4373 | （四） 表 ...

上海市通力律师事务所关于江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会的法律意见书 致:江苏硕世生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受江苏硕世生物科技股份有限公司 (以下简称"公司")的委托,指派本所茹秋乐律师、韩宇律师(以下简称"本所律师") 根据《中华人民共和国公司法》《中华人民共和国证券法》等法律法规和规范性文件(以 下统称"法律法规")及《江苏硕世生物科技股份有限公司章程》(以下简称"公司章 程")的规定就公司 2025年第二次临时股东大会(以下简称"本次股东大会")相关 事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以 了核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中 的所有签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、 完整和有效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 人员资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表 意见,并不对本次股东大会所审 ...

Group 1 - The core viewpoint of the news is that Shuoshi Biotechnology has shown significant stock price performance and trading activity, with a year-to-date increase of 89.73% and a market capitalization of 6.525 billion yuan [1] - As of November 7, the stock price reached 77.80 yuan per share, with a trading volume of 35.4253 million yuan and a turnover rate of 0.55% [1] - The company has experienced net outflows of main funds amounting to 629,500 yuan, while large orders showed a mixed trend with total buy orders of 5.3918 million yuan and sell orders of 6.1871 million yuan [1] Group 2 - Shuoshi Biotechnology, established on April 12, 2010, specializes in the research, production, and sales of in vitro diagnostic products, with a revenue composition of 85.89% from testing reagents [2] - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics, and is involved in various concept sectors including small-cap stocks and high dividends [2] - For the period from January to September 2025, the company reported a revenue of 258 million yuan, a year-on-year decrease of 3.95%, and a net profit attributable to the parent company of 3.1517 million yuan, down 88.38% year-on-year [2] Group 3 - Since its A-share listing, Shuoshi Biotechnology has distributed a total of 1.37 billion yuan in dividends, with 285 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders decreased by 0.94% to 7,620, while the average circulating shares per person increased by 0.94% to 11,006 shares [2][3]

Core Viewpoint - The stock price of Shuoshi Biotechnology has experienced fluctuations, with a year-to-date increase of 85.86% but a recent decline of 2.86% over the past five trading days [2] Group 1: Stock Performance - As of November 4, Shuoshi Biotechnology's stock price was 76.21 CNY per share, with a market capitalization of 6.392 billion CNY [1] - The stock has seen a year-to-date increase of 85.86%, a 2.86% decline in the last five trading days, a 19.26% increase over the last 20 days, and a 36.60% increase over the last 60 days [2] - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 19.7845 million CNY on February 17 [2] Group 2: Financial Performance - For the period from January to September 2025, Shuoshi Biotechnology reported revenue of 258 million CNY, a year-on-year decrease of 3.95%, and a net profit attributable to shareholders of 3.1517 million CNY, down 88.38% year-on-year [3] - The company has distributed a total of 1.37 billion CNY in dividends since its A-share listing, with 285 million CNY distributed over the past three years [4] Group 3: Shareholder Information - As of October 20, 2025, the number of shareholders for Shuoshi Biotechnology was 7,620, a decrease of 0.94% from the previous period, while the average circulating shares per person increased by 0.94% to 11,006 shares [3] - As of September 30, 2025, one of the top ten circulating shareholders, 华夏行业景气混合A (003567), has exited the list [4] Group 4: Business Overview - Shuoshi Biotechnology, established on April 12, 2010, and listed on December 5, 2019, specializes in the research, production, and sales of in vitro diagnostic products, including diagnostic reagents and supporting testing instruments [2] - The company's main revenue sources are diagnostic reagents (85.89%), purchased instruments and materials (7.19%), testing instruments (3.84%), testing services (2.24%), and others (0.84%) [2] - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [2]

Core Viewpoint - The stock price of Shuoshi Biotechnology has experienced significant fluctuations, with a year-to-date increase of 84.68%, but recent trading shows a decline of 2.01% on October 30, 2023, indicating potential volatility in investor sentiment [1][2]. Company Overview - Shuoshi Biotechnology, established on April 12, 2010, and listed on December 5, 2019, is located in Taizhou, Jiangsu Province. The company specializes in the research, production, and sales of in vitro diagnostic reagents and related testing instruments [2]. - The main revenue sources for the company include diagnostic reagents (85.89%), purchased instruments and materials (7.19%), testing instruments (3.84%), testing services (2.24%), and others (0.84%) [2]. Financial Performance - For the period from January to September 2025, Shuoshi Biotechnology reported a revenue of 258 million yuan, reflecting a year-on-year decrease of 3.95%. The net profit attributable to the parent company was 3.15 million yuan, down 88.38% year-on-year [3]. - The company has distributed a total of 1.37 billion yuan in dividends since its A-share listing, with 285 million yuan distributed over the past three years [4]. Shareholder and Market Activity - As of October 20, 2023, the number of shareholders for Shuoshi Biotechnology was 7,620, a decrease of 0.94% from the previous period. The average circulating shares per person increased by 0.94% to 11,006 shares [3]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 19.78 million yuan on February 17, 2023, accounting for 26.20% of the total trading volume [2]. Market Sentiment and Trading Activity - On October 30, 2023, the stock price was reported at 75.73 yuan per share, with a trading volume of 45.34 million yuan and a turnover rate of 0.71%. The total market capitalization stood at 6.352 billion yuan [1]. - The net outflow of main funds was 3.40 million yuan, with large orders showing a buy of 12.05 million yuan (26.58%) and a sell of 15.78 million yuan (34.80%) [1].

江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会会议材料 证券简称：硕世生物 证券代码：688399 江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会 会议材料 2025 年 11 月 11 日 江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会会议材料 江苏硕世生物科技股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》以及《江苏硕世生物科技股份有限公司章程》《江苏硕世 生物科技股份有限公司股东大会议事规则》等相关规定，特制定 2025 年第二次 临时股东大会须知。 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进 入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照复印件（ ...